Why the study?
Does upstream therapy influence atrial fibrillation induction and maintenance?
Does upstream therapy influence atrial fibrillation induction and maintenance?
Answers are grounded in this paper and cite their sources.
This review highlights the potential role of upstream therapies in targeting the arrhythmia substrate for atrial fibrillation management.
Atrial fibrillation is the most common arrhythmia in clinical practice. Ion channel blocking agents are often characterized by limited long-term efficacy and several side effects. In addition, ablative invasive procedures are neither easily accessible nor always efficacious. The "upstream therapy," which includes angiotensin-converting enzyme inhibitors, aldosterone receptor antagonists, statins, glucocorticoids, and ω-3 poly-unsaturated fatty acids, targets arrhythmia substrate, influencing atrial structural and electrical remodeling that play an essential role in atrial fibrillation induction and maintenance. The mechanisms involved and the most important clinical evidence regarding the upstream therapy influence on atrial fibrillation are presented in this review. Some open questions are also proposed.
No takes yet. Share an insight, caveat, or question.
Calò et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: